FILE:LIFE/LIFE-8K-20040105203652.txt.gz
EVENTS:	Regulation FD Disclosure
TEXT:
ITEM: Regulation FD Disclosure
 
 
Item 9. REGULATION FD DISCLOSURE.
     The information contained herein shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by Invitrogen Corporation (the "Company") whether before or after the date hereof, regardless of any general incorporation language in such filing.
     On January 5, 2004, the Company and BioReliance Corporation management made a presentation to employees of BioReliance Corporation regarding Invitrogen's proposed acquisition of all of the outstanding securities of BioReliance Corporation by way of a tender offer that is expected to commence on January 8, 2004.
     The following information set forth in the presentation was not previously disclosed to the public:
The complete presentation is filed as Exhibit (a)(5)(3) to the Company's report on Schedule TO filed on January 6, 2004.
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


